These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23169329)

  • 21. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
    Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
    J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
    Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L
    BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Chi BH; Sinkala M; Mbewe F; Cantrell RA; Kruse G; Chintu N; Aldrovandi GM; Stringer EM; Kankasa C; Safrit JT; Stringer JS
    Lancet; 2007 Nov; 370(9600):1698-705. PubMed ID: 17997151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
    Ramanathan S; Shen G; Cheng A; Kearney BP
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):274-9. PubMed ID: 17414929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
    Nirogi R; Bhyrapuneni G; Kandikere V; Muddana N; Saralaya R; Komarneni P; Mudigonda K; Mukkanti K
    Biopharm Drug Dispos; 2012 Jul; 33(5):265-77. PubMed ID: 22610784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
    Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
    J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
    Chi BH; Ellis GM; Chintu N; Cantrell RA; Sinkala M; Aldrovandi GM; Warrier R; Mbewe F; Nakamura K; Stringer EM; Frenkel LM; Stringer JS
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1099-106. PubMed ID: 19886836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
    J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
    McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
    HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
    Chi BH; Chintu N; Cantrell RA; Kankasa C; Kruse G; Mbewe F; Sinkala M; Smith PJ; Stringer EM; Stringer JS
    J Acquir Immune Defic Syndr; 2008 Jun; 48(2):220-3. PubMed ID: 18520682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of pregnancy on emtricitabine pharmacokinetics.
    Stek AM; Best BM; Luo W; Capparelli E; Burchett S; Hu C; Li H; Read JS; Jennings A; Barr E; Smith E; Rossi SS; Mirochnick M
    HIV Med; 2012 Apr; 13(4):226-35. PubMed ID: 22129166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV.
    German P; Warren D; West S; Hui J; Kearney BP
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):323-9. PubMed ID: 20683270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.